Key Highlights

  • Shares trading down 1.75% to $4.21 in today's session.
  • Trading Volume reached 667.02 thousand shares.
  • The company reported an EPS of negative $0.13.
  • The new biomarker is designed to support patient stratification in prostate cancer clinical trials.

Collaboration Expands Existing Companion Diagnostic Platform

Myriad Genetics, Inc. (NASDAQ:MYGN), a molecular diagnostics and precision medicine company, announced a collaboration with SOPHiA GENETICS and AstraZeneca to advance a new prostate cancer-specific genomic instability score, called PrGIS. The biomarker builds on the company's existing MyChoice companion diagnostic test, currently used in ovarian cancer, now being extended to support a new indication in prostate cancer.

Shares Slip Despite Strategic Rationale

Despite the new collaboration, shares edged lower today, suggesting the announcement alone was not enough to shift broader sentiment on the stock. The company said the Partnership showcases its ability to support biopharma partners in developing precision oncology treatments through patient stratification tools.

EPS Reflects Narrow Losses as Diagnostics Business Evolves

The stock's EPS of negative $0.13 reflects a relatively narrow loss compared to some peers in the diagnostics space, as the company continues to develop new indications for its existing test platforms. Trading volume of 667.02 thousand shares remained within a typical range for the stock.

Outlook: Oncology Conference Data Could Validate New Biomarker

The company plans to present research on the new biomarker, co-authored with AstraZeneca, at a major oncology conference later this year. That presentation may provide further validation of PrGIS and help clarify the commercial opportunity from the new prostate cancer indication.